MONMOUTH JUNCTION, N.J.,
May 19, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical
care leader commercializing its CytoSorb® blood purification
technology to treat deadly conditions in critically ill and cardiac
surgery patients around the world, announces that the Company will
present an overview of the Company's progress and outlook at the
UBS Global Healthcare Virtual Conference and provide a prerecorded
presentation at the Oppenheimer MedTech, Tools and Diagnostic
Summit on Wednesday, May 26, 2021.
Company management will also meet with investors in 1x1
meetings throughout the day. To schedule a meeting with
management, please contact your UBS and Oppenheimer
representative.
CytoSorbents to present at the UBS Healthcare Conference and
Oppenheimer MedTech, Tools and Diagnostic Summit
UBS Healthcare Conference
When: Wednesday, May 26, 2021 from 3:00-3:30PM EDT
Webcast: UBS Healthcare Conference Webcast Link
A live webcast of the presentation will be available at the
above webcast link. An archived replay of the webcast will be
available for 30 days following the event.
Oppenheimer MedTech, Tools and Diagnostic Summit
When: Wednesday, May 26, 2021
Webcast: Oppenheimer Summit Webcast Link
A live webcast of the presentation will be available at the
above webcast link. An archived replay of the webcast will be
available for 90 days following the event.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in treating
life-threatening conditions in critical care and cardiac surgery,
specializing in blood purification. Its flagship product,
CytoSorb® is approved in the European Union with distribution
in 68 countries outside of the US, as an extracorporeal cytokine
adsorber designed to reduce the "cytokine storm" or "cytokine
release syndrome" that may result in massive inflammation, organ
failure and death in common critical illnesses. These are
conditions where the risk of death may be extremely high, yet no
effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators
that can lead to post-operative complications, including multiple
organ failure. CytoSorb® has been used in more than 131,000 human
treatments to date. CytoSorb has received CE-Mark label
expansions for the removal of bilirubin (liver disease), myoglobin
(trauma), and both ticagrelor and rivaroxaban during
cardiothoracic surgery. CytoSorb has also received FDA
Emergency Use Authorization in the
United States for use in critically ill COVID-19 patients
with imminent or confirmed respiratory failure, in defined
circumstances. CytoSorb has also been granted FDA
Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and multiple applications pending, including
ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ™, K+ontrol™, DrugSorb™, ContrastSorb, and
others. For more information, please visit the
Company's websites at www.cytosorbents.com and
www.cytosorb.com or follow us on Facebook and
Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2021, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Contact:
Amy Vogel
(732) 398-5394
avogel@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-ubs-global-healthcare-virtual-conference-and-oppenheimer-medtech-tools-and-diagnostic-summit-301294312.html
SOURCE CytoSorbents Corporation